The Journal of Antimicrobial Chemotherapy (JAC) is among the foremost international journals in antimicrobial research. Our readership includes representatives of academia, industry and health services, and includes those who are influential in formulary decisions. JAC is included in over 3700 consortia subscriptions that span institutions across the globe.
Published monthly, the Journal features original articles on the laboratory aspects and clinical use of antimicrobials including antibacterial, antiviral, antifungal, and antiprotozoal agents and each issue contains Editor’s Choice papers, which are open access to all, offering true value to the scientific, research and healthcare communities.
In addition to the wealth of primary papers, the journal carries review articles offering in-depth discussion on matters of topical concern. Lively leading articles offer incisive coverage of recent advances and controversies.